low - Biopharmaceutical development timelines and FDA approval processes are largely insulated from GDP fluctuations. Rare disease treatments like nOH therapies maintain demand regardless of economic conditions. However, severe recessions could impact partnership valuations and access to capital markets for financing.

Rising interest rates negatively impact TBPH through two channels: (1) higher discount rates compress NPV of future drug cash flows, disproportionately affecting pre-revenue biotechs with distant payoffs, and (2) increased competition from risk-free yields makes speculative biotech investments less attractive, reducing valuation multiples. The company's $950M cash position benefits from higher yields on marketable securities, partially offsetting valuation pressure.

growth - TBPH attracts speculative biotech investors focused on binary FDA approval catalysts and M&A potential. The 101% one-year return reflects momentum following positive clinical/regulatory developments. With negative cash flow and no dividends, the stock appeals to risk-tolerant growth investors willing to underwrite multi-year drug development timelines for asymmetric upside.